This research compares survival outcomes of alemtuzumab and ATG in elderly kidney transplant patients, suggesting careful consideration in medication choice.
ATG induction was associated with improved survival outcomes in our cohort and may be the preferred induction agent in septuagenarians undergoing DDKT versus alemtuzumab. Given the findings of our study, caution is warranted with the use of alemtuzumab in elderly KT patients receiving triple maintenance immunosuppression.
No takes yet. Share an insight, caveat, or question.
Harriman et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: